Purchase Order 75N91019P00336
Award Date 5/24/19
Potential Completion Date 8/22/19
Potential Value $266K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents, to provide an Illumina NextSeq 2000 genetic analysis sequencer. The sequencer will be used to acquire whole genome, whole exome, and whole transcriptome data to support the National Cancer Institute's efforts to develop novel cancer...
- The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $395,850 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract calls for Illumina to provide two Illumina NextSeq2000 Next Generation Benchtop High-Throughput Sequencing Instruments or equivalent equipment to support genomic research at NCI facilities. The solicitation sought quotes for the sequencing instruments to...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $238,017.50 firm fixed price purchase order to Illumina, Inc. for the acquisition of an Illumina NextSeq 2000 sequencing system. The award did not include any set-aside designation. The sequencing system will support the National Cancer Institute's Surgery Branch in developing novel immunotherapies for the treatment of various cancers, including melanoma, gastrointestinal, lung, and...
- This is a $202,000.00 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. for the provision of an Illumina NextSeq 500 sequencing system. The contract has no set-aside designation. Through past contract awards, Illumina has provided a range of genomic sequencing instruments, reagents, and support services to various federal agencies including the NIH, Centers for Disease Control and...
- <p>The National Cancer Institute awarded a purchase order to Illumina, Inc., valued at $239,190.00, for procurement of an Illumina NextSeq 2000 sequencing system and trade-in of an Illumina NextSeq 500 sequencing system, with an award date of August 26, 2020. Place of performance is San Diego, California. The order was structured as a firm fixed-price purchase order with no set-aside designation and carries an ultimate completion date of October 28, 2020.</p>
- This federal contract award is for the purchase of (QTY 2) Illumina NextSeq 550Dx sequencers by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI). The total potential value of the firm fixed price purchase order is $630,846.00. The contract was awarded to the prime vendor Illumina, Inc., a manufacturer of genomic sequencing and analysis products. The sequencing systems are intended to support the NCI's clinical next-generation...
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Illumina, Inc., a manufacturer of genetic sequencing instruments and consumables. The contract is for Illumina's NextSeq 500 Sequencing System Production Care comprehensive support plan, with a potential value of $145,851.23 and a completion date of January 31, 2023. Illumina has previously received awards from federal agencies like the...
- This firm fixed-price purchase order was awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), to Illumina, Inc. for the procurement of one (1) Illumina NextSeq 550 DX Sequencing System. The $281,764 contract supports the NCI's Comprehensive Oncologic Molecular Pathology and Sequencing Service (COMPASS) and has an ultimate completion date of September 6, 2024. The system must be capable of sequencing DNA libraries using in vitro diagnostic...
- This is a $114,198.14 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for their NextSeq 550 comprehensive service plan. The contract is not set aside and has an ultimate completion date of July 31, 2024. Illumina is a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, and has previously received prime federal contracts and subcontracts from agencies...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) awarded a $178,500.00 firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of genomic analysis instruments and reagents, for the purchase of a NextSeq 500 sequencing system. This award supports the NIH's research and diagnostic needs, as Illumina has provided a range of sequencing systems and consumables to HHS, the Centers for Disease Control and Prevention, the Department of...